How to Determine Product Classification for Medical Device Registration in Egypt

Direct Answer

To determine the product classification for medical device registration in Egypt, a manufacturer should first confirm the target country, the product's risk class, the applicable regulatory pathway and the existing basis of documentation, and only then assess the technical file, quality management system (QMS), labels and instructions for use (IFU), local agent arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that the project timeline is not extended by unclear classification, incomplete evidence or undefined authorisation arrangements.

Published: 11 July 2026 16:28  |  Updated: 11 July 2026 16:28

This FAQ addresses the questions manufacturers most often need to resolve first in international registration projects, covering dossier preparation, compliance pathways and post-market maintenance.

Key Takeaways

• Classification cannot be judged in isolation: risk class, intended use, regulatory pathway and the existing documentation base must be assessed together.
• For Chinese manufacturers, the most reliable approach is to complete a product classification and documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.
• Target-market registration typically affects the technical file, authorised representative, importer cooperation, label language, QMS evidence and subsequent change maintenance at the same time.
• If a project is driven only by the question of "which documents must be submitted", deficiencies and rework are likely to arise in model coverage, evidence-chain consistency, label claims and certificate control.
• AIMEILI recommends planning this question within a GHWP member-state and multi-country access strategy, using one reusable core technical file to support localisation in different markets rather than rebuilding documentation country by country.

Applicable Scenarios and Core Questions

Manufacturers searching for guidance on how to determine product classification for Egypt registration are usually not looking for a conceptual explanation. What they need to resolve is whether their existing documentation can support a submission in the target market, whether a local agent or authorised representative is required, why timelines become extended, and which issues could affect the launch plan. Behind this single question there are usually several connected topics: product classification, registration pathway, evidence chain, label localisation and post-market maintenance responsibility.

If a manufacturer plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the question for one country alone is insufficient. A more valuable approach is to first build reusable versions of the core technical file, QMS evidence, performance verification, clinical evidence and labels/IFU, and then localise them according to each country's regulatory requirements.

Registration Assessment Logic

A manufacturer should first confirm the intended purpose, mechanism of action, conditions of use, manner and duration of body contact, sterility, whether the device is active, and whether it contains software or has an IVD character. Only then can the risk class and the submission pathway be determined. If the pathway is judged incorrectly, all subsequent translation, notarisation, authorisation, testing and supplementary documentation will move in the wrong direction.

For a target-market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who handles regulatory communication, who manages importation and post-market incidents, who triggers changes, and who maintains renewal documentation. If these points are left vague in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or other applicable QMS evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and IFU, authorisation documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended purpose, not on how many files have been uploaded.

Common Mistakes

• Treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.
• Translating domestic NMPA documentation directly and submitting it without restructuring the evidence according to the target-market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labels do not provide sufficient coverage.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between labels, IFU, promotional materials and registration claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, so that each country requires separate preparation and both cost and timeline are multiplied.

Manufacturer Preparation Checklist

Before starting a project, manufacturers are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English IFU.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorised representative.
• Establish a target-country gap assessment table identifying what must be retested, translated, notarised or supported by additional declarations.

AIMEILI's Perspective

AIMEILI advises manufacturers not to treat target-market registration as a one-off document submission, but to manage it as an overseas market access programme. For manufacturers entering several countries, building a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster, more stable and more favourable for subsequent changes and renewals than compiling documentation on an ad hoc basis for each country.

From a project management perspective, three matters should be controlled at the earliest possible stage: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. Unless these three points are clear, a project may still encounter repeated rounds of deficiency responses, agent communication and post-market maintenance issues, even when the documentation appears extensive.

Frequently Asked Questions

Can domestic documentation be used directly for target-market registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as-is. The documentation structure, language, labels, authorisation documents and evidence chain must be adjusted in line with local regulatory requirements.

When is the best time to start a gap assessment?

Immediately after the target market and product list have been confirmed. The earlier the gap assessment is completed, the sooner retesting, translation, label adjustments and agent selection can be arranged.

Why does the choice of local agent affect registration quality?

The local agent is typically involved in registration communication, changes, renewal and the handling of post-market incidents. If responsibilities are unclear, certificate control and subsequent market stability may be affected.

Implementation Recommendations

When executing this type of registration project, manufacturers should establish a project ledger that manages the product list, model and specification matrix, registration pathway, document owners, translation status, testing status, records of communication with the local agent and expected submission dates in a single table. This makes documentation gaps visible in good time and helps management judge whether the project will affect the launch plan.

For manufacturers with existing registrations in several countries, an evidence reuse matrix should also be established, specifying which documents can serve as core evidence and which must be reissued or supplemented with explanatory statements in accordance with national requirements. In particular, labels and IFU, clinical evaluation, risk management, performance verification and QMS certificates must be kept at consistent versions.

• Confirm the target market and product list.
• Complete the risk classification and pathway determination.
• Establish the documentation gap assessment table.
• Define the local agent and certificate control arrangements.
• Track translation, notarisation, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, QMS documentation is not an isolated certificate. Regulators generally examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope of the ISO 13485 certificate does not match the product being filed, or if the manufacturing site, model and specification matrix and IFU version do not align with the test reports, additional clarification may be requested even when a large number of documents have been prepared.

Manufacturers should establish an evidence consistency checklist before submission, matching the product name, model and specification matrix, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version and QMS certificate item by item. This step appears basic, but it can significantly reduce the probability of deficiency letters, and it is particularly valuable for projects filed simultaneously in several GHWP member states or for multiple product families.

Localisation and Authorised Representative Responsibilities

Target-market registration projects usually involve arrangements with a local agent, authorised representative, importer or registration holder. Manufacturers need to confirm in advance whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different boundaries of responsibility directly affect certificate control and subsequent market stability.

Labels, IFU and authorisation documents also cannot simply be translated. Manufacturers should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative information and after-sales contact details. For manufacturers that already hold CE, FDA, NMPA or other market documentation, the focus of localisation is to convert reusable evidence into a submission structure accepted by the target country, rather than drafting a separate and isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Manufacturers must also maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall procedures, label versions and records of regulatory updates. Many manufacturers invest heavily in obtaining the certificate but neglect post-market maintenance, so that a change of manufacturing site, expansion of models, IFU update or replacement of the agent can later disconnect the certificate from actual market sales.

AIMEILI recommends managing this question within an annual international registration plan: first define target-market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only greater efficiency in a single country, but also the development of a repeatable overseas compliance capability that reduces the cost of rebuilding documentation from scratch each time a new market is entered.

Further Reading

• Previous: Egypt Medical Device Registration: How Should Registration Documentation Be Prepared?
• Next: Egypt Medical Device Registration: How Should the Technical File Be Compiled?
• Philippines Medical Device Registration: What Are the Requirements for the Risk Management File?
• Philippines Medical Device Registration: How Should Performance Verification Documentation Be Prepared?
• Philippines Medical Device Registration: What to Do When Quality System Evidence Is Inconsistent?
• Singapore Medical Device Registration: How Should Registration Documentation Be Prepared?
• Singapore Medical Device Registration: How Is Product Classification Determined?
• Singapore Medical Device Registration: How Should the Technical File Be Compiled?

Return to the FAQ Centre  |  News & Insights  |  Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principles: Priority is given to official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of application: This article supports preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target-country regulator, testing conclusions or legal advice. The specific project should be based on the latest requirements of the target-country regulator and the actual documentation basis of the product.